RxSight price target lowered to $6.50 from $8 at BofA
BofA lowered the firm's price target on RxSight to $6.50 from $8 and keeps an Underperform rating on the shares. The firm notes the company pre-announced preliminary Q2 sales of $27M vs Street of $32M and lowered 2026 guidance by $13M at midpoint. RxSight pointed to elevated levels of competitive trialing and lower con